Section of Developmental Pharmacology and Experimental Therapeutics, The Children's Mercy Hospital and Clinics, Kansas City, MO 64108 , USA.
Clin Chem Lab Med. 2010 May;48(5):627-33. doi: 10.1515/CCLM.2010.128.
Gene copy number variations (CNVs) are increasingly recognized to play important roles in the expression of genes and hence on their respective enzymatic activities. This has been demonstrated for a number of drug metabolizing genes, such as UDP-glucuronosyltransferases 2B17 (UGT2B17) and sulfotransferase 1A1 (SULT1A1), which are subject to genetic heterogeneity, including CNV. Quantitative assays to assess gene copy number are therefore becoming an integral part of accurate genotype assessment and phenotype prediction.
In this study, we evaluated a microfluidics-based system, the Bio-Rad Experion system, to determine the power and utility of this platform to detect UGT2B17 and SULT1A1 CNV in DNA samples derived from blood and tissue. UGT2B17 is known to present with 0, 1 or 2 and SULT1A1 with up to 5 gene copies.
Distinct clustering (p<0.001) into copy number groups was achieved for both genes. DNA samples derived from blood exhibited less inter-run variability compared to DNA samples obtained from liver tissue. This variability may be caused by tissue-specific PCR inhibitors as it could be overcome by using DNA from another tissue, or after the DNA had undergone whole genome amplification.
This method produced results comparable to those reported for other quantitative test platforms.
基因拷贝数变异(CNVs)越来越被认为在基因表达及其相应的酶活性中发挥重要作用。这已在许多药物代谢基因中得到证实,如 UDP-葡萄糖醛酸基转移酶 2B17(UGT2B17)和磺基转移酶 1A1(SULT1A1),它们存在遗传异质性,包括 CNV。因此,定量测定基因拷贝数正在成为准确基因型评估和表型预测的一个组成部分。
在这项研究中,我们评估了基于微流控的系统,即 Bio-Rad Experion 系统,以确定该平台在检测血液和组织来源的 DNA 样本中 UGT2B17 和 SULT1A1 CNV 方面的能力和实用性。已知 UGT2B17 存在 0、1 或 2 个基因拷贝,SULT1A1 最多有 5 个基因拷贝。
两个基因的拷贝数分组都实现了明显的聚类(p<0.001)。与来自肝组织的 DNA 样本相比,来自血液的 DNA 样本的运行间变异性较小。这种变异性可能是由组织特异性 PCR 抑制剂引起的,因为可以通过使用另一种组织的 DNA 或在 DNA 经历全基因组扩增后克服这种变异性。
该方法产生的结果与其他定量测试平台报告的结果相当。